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Abstract
Background: The 2007 WHO guidelines for the treatment of osteoporosis require that we know the population risk of an osteoporotic 
fracture for each country to classify patients requiring treatment. 
Material and methods: Studies have been carried out among a random cohort of 1,608 women over the age of 40 to assess a ten-year 
absolute risk of main osteoporotic fractures (AR-10 m.o.fx.) and hip fractures (AR-10 h.fx.) by using FRAX®BMI and FRAX®BMD based 
on the epidemiology of fractures in England. 
Results: Both methods gave similar results in assessing the probability of fracture, showing the increase of AR-10 m.o.fx. in subsequent life 
decades to rise from 5% in the fifth decade to 25% in the ninth, mean result 11%, and AR-10 h.fx. to rise over the same period from 0.5% to 
13%, mean result 3%. The number of fractures increases up to the seventh and eighth decades, and decreases according to the number of 
patients in the age group. The commonest fracture risks reported, other than old age and low BMI, were a prior fracture, a family history 
of hip fracture and smoking. 
Conclusions: Comparative analysis of examined parameters of FRAX between people with and without fractures showed considerable 
differences only in age and AR-10 m.o.fx. This doubled in people with previous fractures (ca. 18% vs. 9%) and AR-10 h.fx. (ca. 5% vs. 2.5%). 
The “middle” area between the average population risks (AR-10 m.o.fx. 11% and AR-10 h.fx. 3%) and the risks in patients with fractures 
(AR-10 m.o.fx. 18% and AR-10 h.fx. 9%) could work as an indicator: below those values the risk is low and no treatment is required; above 
those values, the risk is high, and intervention is necessary; the middle area implies a BMD examination and reassessment of the fracture 
risk. (Pol J Endocrinol 2011; 62 (4): 290–298)
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Streszczenie
Wstęp: Schemat Światowej Organizacji Zdrowia (WHO) z 2007 roku postępowania wobec osteoporozy prowadzący do identyfikacji osób 
potrzebujących leczenia, aby zmniejszyć ryzyko złamania, stawia wymóg znajomości w każdym kraju poziomu populacyjnego zagrożenia 
złamaniami osteoporotycznymi. 
Materiał i metody: Podjęto badania oceny 10-letniego prawdopodobieństwa głównych złamań osteoporotycznych (RB-10 g.z.op.) i złamań 
biodra (RB-10 b.) na niewyselekcjonowanej grupie 1608 kobiet po 40. roku życia, posługując się narzędziem FRAX®BMI i FRAX®BMD 
wzorowanym na epidemiologii złamań w Anglii. 
Wyniki: Obydwa sposoby podobnie oceniły prawdopodobieństwo złamania i w kolejnych dekadach życia ujawniły rosnące RB-10 g.z.op. 
od ok. 5% w 5. dekadzie do 25% w 9., średnio 11%, oraz RB-10 b. odpowiednio od 0,5% do 13%, średnio 3%. Liczba złamań rosła do 
7. i 8. dekady i malała zgodnie z liczebnością grupy wiekowej. Najczęściej zgłaszanymi czynnikami ryzyka, poza zaawansowanym wiekiem 
i niskim BMI, były: przebyte uprzednio złamanie, palenie tytoniu i złamanie biodra w wywiadzie rodzinnym. 
Wnioski: Analiza porównawcza badanych parametrów FRAX osób z złamaniami i bez nich wykazała znamienne statystycznie różnice wy-
łącznie pod względem wieku i dwukrotnie wyższe RB-10 g.zop. osób ze złamaniami (ok. 18% vs. 9%) i RB-10 b. (ok. 5% vs. 2,5%). Przestrzeń 
„pośrednia” pomiędzy średnim ryzykiem populacyjnym (RB-10 g.z.op. 11% i RB-10 b. 3%) a ryzykiem osób ze złamaniami (RB-10 g.z.op. 
18% i RB-10 b. 9%) mogłaby posłużyć jako punkt orientacyjny: poniżej wymienionych wartości — ryzyko małe, niewymagające leczenia, 
powyżej — ryzyko duże wymagające interwencji, zaś ta „pośrednia” stanowi wskazanie do badania BMD i ponownej analizy zagrożenia 
złamaniem. (Endokrynol Pol 2011; 62 (4): 290–298)
Słowa kluczowe: osteoporoza, epidemiologia złamań, próg interwencji leczniczej
Janusz E. Badurski, Polska Fundacja Osteoporozy, ul. Waryńskiego 6/2, 15–461 Białystok, Poland,
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Introduction
Defining osteoporosis on the basis of BMD (T-score of 
minus 2.5) [1] does not fully reflect its nature or clinical 
manifestation i.e. susceptibility to low-energy fractures 
(= osteoporotic fractures) and its consequences. That 
has been proven by research that judged osteoporotic 
fractures against BMD. All of the research [2–5] shows 
that most fractures, including proximal femur (‘hip 
fracture’ for short) happen with BMD at the femoral 
neck above a T-score of  minus 2.5, which was the WHO 
criterion for defining osteoporosis in 1994.
That resulted in intervention being offered only to 
individuals with low BMD (a T-score of less than minus 
2.5). That complied with drugs registration and medical 
expense reimbursement rules.
It has become clear that factors other than low BMD 
affect bone strength and susceptibility to fracture. 
A number of clinical risk factors (CRFs) independent 
of BMD and individually sufficient to increase the risk 
have been examined by a series of meta-analyses of frac-
ture epidemiology. They are: old age, low BMI, history 
of osteoporotic fracture, family history of hip fracture, 
low BMD, chronic glucocorticosteroids use, rheumatoid 
arthritis (with possible other secondary osteoporosis), 
excessive alcohol consumption and smoking [6, 7].
A great deal of global research has taken place to 
formulate a WHO algorithm determining the risk of 
fracture and whether there is a need for interven-
tion (intermediate risk: should be verified by a BMD 
screening, low risk: no intervention required, high risk: 
treatment required). FRAX® is a risk assessment tool 
which combines the independent fracture risks into 
one parameter: a ten-year total (absolute) probability 
of an osteoporotic fracture (AR-10) [8].
At present, individuals with BMD above a T-score 
of minus 2.5 with fractures (most cases) or with a high 
probability of an osteoporotic fracture, are not diag-
nosed with osteoporosis. This leads to the self-contra-
dictory conclusion that a patient has had an osteoporotic 
fracture but does not suffer from osteoporosis. Oste-
oporosis (T-score: minus 2.5) is thus only one of several 
reasons for excess bone brittleness and looking solely 
at osteoporosis means ignoring other reasons for lower 
bone strength. Clinically, it is not the diagnosis of oste-
oporosis but the assessment of an individual probability 
of fracture, whatever its cause, that determines for the 
doctor which patient should be given treatment. Treat-
ment equals decrease of fracture risk. 
Who then should be given treatment? Patients with 
high risk of fracture obviously.  But at what AR-10? One 
criterion is cost effectiveness (which is cheaper: pharma-
cotherapy or intervention after the first or subsequent 
fractures?) That means learning the data representa-
tive of the whole country as well as pricing the cost of 
treatment. As drugs are available at a whole range of 
prices, and aimed at patients with differing BMDs, their 
effectiveness depends on the degree of BMD lowering. 
We have no such data in Poland. Applying data from 
another country would help. If not, we could create our 
own locally-based points of reference.
The aim of this study was:
 — to determine the mean ten-year probability of 
the main osteoporotic fractures and hip fractures 
(AR-10 m.o.fx. and AR-10 h.fx.) in women over 
40 years of age living in the region of Bialystok, by 
using FRAX® with BMI (FRAX/BMI) and with BMD 
(FRAX/BMI) separately;
 — to analyse the differences between fracture risk for 
patients with and without previous osteoporotic 
fractures;
 — to identify intervention thresholds applicable in 
Poland;
 — to identify the most efficient treatment for certain 
patients and who would not benefit from treatment 
at all.
Material and methods
The subject of this epidemiological analysis was a cohort 
of 1,608 non-selected women living in the region of Bia-
lystok, aged 40 to 89, average age 63.9. They underwent 
epidemiological examination and were diagnosed, for 
different reasons, in the Centre for Osteoporosis and 
Osteo-Articular Diseases in Bialystok. Apart from BMD 
screening, they were asked to fill in a questionnaire 
on various risk factors, being FRAX components. Fi-
gure 1 shows age distribution in the BOS-2 cohort.
Having established the age, weight, height and 
BMI (kg/m2), the following were recorded: evidenced 
low-energy fracture, over 40 years of age, hip fracture 
in parent, chronic, more than 12 months’ glucocortico-
steroids use, rheumatoid arthritis, long-lasting smok-
ing and alcohol abuse. All participants were screened 
for BMD at neck and total proximal femur as well as 
L1-L4 vertebrae using DXA with Hologic QDR4500SL. 
Still, only 1107 women held all the documentation 
necessary for FRAX/BMD calculation. The calcula-
tion included a ten-year probability of fracture at the 
proximal femur (so-called “hip fracture”) (AR-10 h.fx.) 
and altogether at all main sites (AR-10 m.o.fx.), mean-
ing hip, clinical vertebra fracture, Colles’ fracture and 
proximal humerus fracture. A computer-driven form 
of FRAX® (FRAX-WHO Fracture Risk Assessment 
Tool) of 2008 was used, with BMI and BMD [8]. It was 
based on the epidemiology of fracture among women 
in England and is currently being popularised by the 
WHO report [6] and the European Guidances from 
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the ESCEO and IOF [7]. The statistical analysis of the 
differences in the contrasted groups was made using 
a t-student test.
Results and discussion
The commonest CRFs in the BOS-02 cohort were low 
BMI at relative risk (RR) below 1.0, history of an oste-
oporotic fracture, smoking, family history of hip frac-
ture, and rheumatoid arthritis.
The percentage of women who have sustained 
an osteoporotic fracture increases with age (Figure 2). 
In the sixth decade, one in six has had a fracture 
(16.82%), in the seventh decade it is 29.24% and in the 
eighth decade it is 33.46%. Over the age of 80, almost 
half of women have suffered a fracture (44.44%), the 
mean result being that 27.05% of women over the 
age of 40 suffer a low-energy fracture. The number 
of fractures complies with the age distribution in the 
BOS-2 cohort, the lowest over the age of 80, in a group 
of only 27 females (Figure 3).
Age, BMI and BMD calculations and data from 
medical history were used to assess an individual, 
total/absolute ten-year probability of fracture at the 
main osteoporotic locations (AR-10 m.o.fx.) and hip 
(AR-10 h.fx.) using the FRAX tool in two versions with 
BMI and BMD – FRAX/BMI and FRAX/BMD via the 
internet, as shown in Figures 4 and 5.
The AR-10 m.o.fx. results calculated with BMI and 
BMD show considerable similarities: there is a four-fold 
increase between the sixth and ninth decades, with 
mean results at 11.0–11.8%. There is also a noticeable 
two-fold increase of risk between the ages of 50 and 
70 and another one between the ages of 70 and 90. 
Figure 1. BOS-2: number of women/observations and age distribution in the population of 1,608 women
Rycina 1. BOS-2: liczebność kobiet/obserwacji i dystrybucja wieku w populacji 1608 kobiet
Figure 2. BOS-2: frequency of clinical fracture risks
Rycina 2. BOS-2: częstotliwość występowania klinicznych czynników ryzyka
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Figure 5 illustrates a similar increase in the risk of 
hip fracture. Every decade of life increases the risk 
twice; in the ninth decade it is five times higher than 
the intermediate risk (2.8–3.1%).
Is there a relationship between the current BMD 
screenings (which manifest results lower than in 
the past) and the history of an osteoporotic fracture 
(Figure 6)? The BOS-2 cohort was divided into two 
groups. One with a T-score for the femoral neck below 
minus 2.5 (osteoporosis), the other with a T-score above 
minus 2.5 (norm), where the mean T-score was minus 
1.4- minus 1.5, indicating an osteoporosis T-score of 
minus 3.1. There were 18% of cases with osteoporosis 
in the group without fracture and 29% in the group 
with fractures (in 71% of normal BMD readings).
Table I illustrates different parameters in patients with 
and without fractures. Significant statistical differences 
were present only in the case of age (63.1 years without 
fractures, 66.5 years with fractures) and analysis with 
the FRAX/BMI and FRAX/BMD tools,both in the cases of 
AR-10 m.o.fx., and AR-10 h.fx. AR-10 was twice as high in 
individuals with fractures than in those without.
Mean AR-10 results in the whole cohort AR-10 m.o.fx. 
approx. 11% and AR-10 h.fx. approx. 3% and mean 
AR-10 of women with previous fractures approx. 18% 
and approx. 5% respectively can be used as reference 
values to assess the need for treatment in a population 
represented by the BOS-2 cohort. What is the signifi-
cance of the particular CRF? The influence of each re-
ported CRF on the number of females with AR-10 above 
Figure 3. BOS-2: number of individuals with and without fractures according to life decades in a population of 1,608 women aged 40–89
Rycina 3. BOS-2: liczba osób bez i ze złamaniami w poszczególnych dekadach życia w populacji 1608 kobiet w wieku 40–89 lat
Figure 4. BOS-2: ten-year probability of main osteoporotic fracture (femoral neck, vertebral column, Colles’ fracture) (AR-10 m.o.fx.) 
calculated with FRAX®BMI and FRAX®BMD
 Rycina 4. BOS-2: 10-letnie ryzyko głównych złamań osteoporotycznych (szyjki kości udowej, kręgosłupa, k. ramiennej i złamanie 
Collesa) RB-10 g.z.op. wyliczone narzędziami FRAX®BMI i FRAX®BMD
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Table I. BOS-2: Statistical differences between women with and without previous fracture in the BOS-2 cohort calculated 
using FRAX®BMI and FRAX®BMD
Tabela I. BOS-2: Analiza statystyczna różnic pomiędzy kobietami z przebytym złamaniem i bez niego w kohorcie BOS-2 
oceniana sposobem FRAX®BMI i FRAX®BMD
Mean without fractures 
(n = 1173)
Mean with fractures 
(n = 435)
P
Age (years) 63.1 66.5 < 0.001
BMI [kg/m2] 27.7 28.0 NS
BMD Z-score 0.02 –0.05 NS
BMD in femoral neck [g/cm2] 0.74 0.73 NS
Family history of hip fracture (yes/no) 11% 13% NS
Rheumatoid arthritis (yes/no) 7% 7% NS
Glucocorticosteroids use (yes/no) 2% 3% NS
Smoking (yes/no) 16% 13% NS
Excess alcohol consumption (yes/no) 0% 1% NS
AR-10 m.o.fx. FRAX®BMI (%) 8.4% 18.2% < 0.001
AR-10 m.o.fx. FRAX®BMD (%) 9.4% 17.5% < 0.001
AR-10 h.fx. FRAX®BMI (%) 1.9% 5.3% < 0.001
AR-10 h.fx. FRAX®BMD (%) 2.3% 5.0% < 0.001
18% compared to those below 18% may be contributory. 
That could help identify the so-called ‘strong CRF’ in the 
whole examined cohort. That is shown in Figures 7–13.
In the population of 1,078 females, approximately 
85.8% were burdened with RB-10 below 18% and 
14.19% had RB-10 above 18%. The latter figure increases 
with age; only in the ninth decade does it become in-
versely proportional.
Every single CRF increases the number of individu-
als with AR-10 above 18% by 6%.
Family history of hip fracture doubles the number 
of individuals with AR-10 above 18%.
Figure 5. BOS-2: Ten-year probability of hip fracture (AR-10 h.fx.) calculated with FRAX®BMI and FRAX®BMD
Rycina 5. BOS-2: 10-letnie ryzyko złamań b.k.k.u. (biodra) RB-10 b. wyliczone narzędziami FRAX®BMI i FRAX®BMD
A previous fracture increases the number of indi-
viduals with AR-10 above 18% by 5.5-fold.
Of 14 individuals with chronic steroid use, half were 
burdened with AR-10 above 18%, which constituted the 
group with the highest probability of an osteoporotic 
fracture.
Active smoking and excessive alcohol consumption 
seem to be weak CRFs. But only seven patients acknowl-
edged these facts in their medical record. 
The analysis of the level of significance of par-
ticular risk factors proves that long-term glucocor-
ticosteroids use, family history of hip fracture, and 
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past hip fracture represent serious danger, as has 
long been known.
Discussion
The application of the WHO algorithm is becoming 
more and more widespread. However, in order to 
reach an agreement on an appropriate threshold to 
identify patients for intervention, the data needs to 
be tailored to national requirements. The algorithm 
implies the need for AR-10 screening (individual, 
absolute risk of fracture), and correctly classifies it 
into low, intermediate and high. High risk requires 
intervention without any additional screening. Inter-
mediate risk implies a BMD examination and reassess-
ment of fracture risk. With low risk, no intervention 
is required. 
Figure 6. BOS-2: osteoporotic fractures against “densitometric 
osteoporosis”
Rycina 6. BOS-2: złamania osteoporotyczne vs. „osteoporoza 
densytometryczna”
Figure 7. BOS-2: influence of age (life decades) on the number of individuals with AR above 18%
Rycina 7. BOS-2: wpływ wieku (dekad życia) na odsetek osób z RB-10 powyżej 18%
Figure 8. BOS-2: influence of the number of risk factors on the number of individuals with AR-10 above 18%
Rycina 8. BOS-2: wpływ liczby czynników ryzyka na odsetek osób z RB-10 powyżej 18%
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Our points of reference were the mean AR-10 in the 
population and the part of the population that had suf-
fered an osteoporotic fracture, which confirms the dia-
gnosis of osteoporosis. The frequency of occurring/re-
porting particular CRFs and their influence contribute 
additional information on the Polish population. The 
analysis was performed on a group of 1,608 women over 
the age of 40 that we had at our disposal in our database 
at the Centre for Osteoporosis and could be used ad hoc. 
The group comprised non-selected females, although 
not selected by blind choice. All the subjects had been 
asked questions on CRF, which is a FRAX requirement. 
The age distribution was typical for a cohort of post-
menopausal women and comparable to the BOS-1 [4, 
5] screening. AR-10 m.o.fx. and AR-10 h.fx. results cal-
culated with FRAX/BMI and FRAX/BMD proved similar. 
More significant differences were reported only in the 
ninth decade of life.
The average value of AR-10 m.o.fx. with and without 
BMD was approximately 11%, the value of AR-10 h.fx. 
was approximately 3%. AR-10 m.o.fx. in the case of 
individuals with past low-energy fractures with and 
without BMD was above 18% and AR-10 h.fx. was 5%.
The above data were held as reference points. 
Figure 10. BOS-2: influence of previous fracture on the number 
of individuals with AR-10 above 18%
Rycina 10. BOS-2: wpływ przebytego złamania na odsetek osób 
z RB-10 powyżej 18%
Figure 9. BOS-2: influence of hip fracture in parent on the number 
of individuals with AR-10 above 18%
Rycina 9. BOS-2: wpływ złamania biodra u rodziców na odsetek 
osób z RB-10 powyżej 18%
Figure 11. BOS-2: influence of long-term glucocorticosteroids use 
on the number of individuals with AR-10 above 18%
Rycina 11. BOS-2: wpływ glikokortykoidosteroidoterapii na 
odsetek osób z RB-10 powyżej 18%
Figure 12. BOS-2: influence of active smoking on the number of 
individuals with AR-10 above 18%
Rycina 12. BOS-2: wpływ aktywnego palenia na odsetek osób z 
RB-10 powyżej 18%.
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We consider AR-10 m.o.fx. and AR-10 h.fx. below 
the middle population risk in each life decade (i.e. on 
average below AR-10 m.o.fx. 11%, and/or AR-10 h.fx. 
3%) as “low” risk. “High” risk means AR-10 m.o.fx. 
above 18%, the mean value of AR-10 in women with 
previous fractures. “Intermediate” risk is then between 
those values of mean population AR-10 (11%), and the 
mean value of patients with fractures (18%). These make 
it possible to classify patients according to those three 
groups at the first appointment at primary health care 
level by using mean values and the FRAX®BMI tool 
without the necessity for BMD screening. AR-10 m.o.fx. 
higher than 11% and/or AR-10 h.fx. higher than 3% are 
indications for Hip BMD by DXA measurements and 
for AR-10 recalculation with FRAX/BMD. Values above 
AR-10 18% should be considered as “high” probability 
requiring pharmacological intervention.
There is a lively debate as to whether one interven-
tion threshold for all patients is more justified than 
one threshold proportionate to each life decade [9, 
10]. Most opinion-formers advocate the latter, giving 
priority to the life risk of a younger individual who 
will live longer. Therefore, younger people have their 
intervention thresholds set much lower than older 
patients. Such a solution is currently supported by 
the Polish Society for Osteoarthrology, the Polish 
Foundation of Osteoporosis, and the Multidisciplinary 
Forum on Osteoporosis, who promote an easy-to-use 
AR-10 calculator with therapeutic data adequate for 
each age [11].
Using the FRAX methodology, Johnell points to 
AR-10 m.o.fx. over 14% as being the cost-effective 
threshold [12].  In the USA, AR-10 h.fx. above 3% 
is the threshold for intervention[13, 14].  In Japan, 
AR-10 m.o.fx. from 5% in the sixth decade to 20% in 
the ninth [15]. Similar intervention tresholds were con-
sidered for Poland in 2007 [11]. In Belgium, a previous 
fracture suffices to refund the cost of treatment and 
RB-10 g.z.op. ranges between 7.5% at 50 years of age 
to 26% at 80 [16]. In England, the cost-effective thresh-
old of risedronate therapy is AR-10 m.o.fx. at 13% [17]. 
The use of the FRAX tool in the USA classifies 37% of 
women over 50 for treatment and reduces the number 
of patients for intervention by 20% in relation to the 
previous recommendation [18].
27% of postmenopausal women would require inter-
vention if we agreed on AR-10 m.o.fx. above 18% (indi-
viduals with previous fracture) as indicating “high” risk. 
In another Polish analysis, with 94 participants, 20.2% 
of females aged 55–79 would require treatment if all 
osteoporotic fractures were intervention indicators [19].
Since 31 May, 2008 it has been the EMEA (European 
Medicines Agency) condition that if a medicine is to be 
registered “for treatment of osteoporosis in postmeno-
pausal women with high fracture probability,” screen-
ings for the drug’s effectiveness in females with over-
population risk need to be done regardless of BMD [20].
Pharmacotherapy for individuals at high probability 
of fracture with BMD characteristic of osteopenia poses 
a problem. Most registered and reimbursed antiresorp-
tives are active only at low BMD, below a T-score of 
minus 2.5. Consequently, the patient’s BMD, as well as 
the proposed drug’s efficacy, need to be identified prior 
to intervention. For instance, it will not be successful to 
treat a patient with AR-10 30% and BMD at a T-score 
for example of minus 1.8 with alendronate, which is 
a reimbursed drug.
Our BOS-2 population is characterised by the fre-
quency of particular CRFs (low BMI, past osteoporotic 
fracture, smoking and hip fracture in parent) and the in-
fluence grading (previous fracture, glucocorticosteroids 
use, family history), which makes it easier to identify 
patients for intervention in outpatient healthcare.
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